FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to compound of formula (Ip1) 
or (Ip3) 
or its pharmaceutically acceptable salt, where G1 represents (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)halogenalkyl, (C1-C4)halogenalkoxy, halogen, cyano or nitro; n equals 0; G2a represents (C3-C4)cycloalkyl or (C3-C4)cycloalkyl(C1-C2)alkyl; G2b represents hydrogen; R1 represents methyl or ethyl; R2 represents phenyl or fluorophenyl; and R3 represents 2-hydroxy-2-methylpropyl or 2-methyl-2-cyanopropyl.
EFFECT: invention relates to application of compound of formula (Ip1 and Ip3) for manufacturing medication or pharmaceutical composition, intended for treating a person with disease or state, selected from type II diabetes mellitus, obesity, glucose intolerance, hyperglycemias, hyperlipidemis, insulin resistance, decrease of cognitive functions and dyslipidemia.
5 cl, 6 tbl, 107 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID-DEHYDROGENASE 1 | 2009 |
|
RU2531272C2 |
| CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND USE THEREOF IN TREATING PSYCHOTIC DISORDERS | 2011 |
|
RU2586974C2 |
| CONDENSED DERIVATIVES OF IMIDAZOLE AND PYRAZOLE AS MODULATORS OF ACTIVITY TNF | 2014 |
|
RU2686117C1 |
| FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2679914C9 |
| DERIVATIVES OF CARBOXYLIC ACIDS (VARIANTS), PHARMACEUTICAL COMPOSITION AND METHOD FO SELECTIVE BINDING αβ-INTEGRIN IN MAMMAL | 2000 |
|
RU2263109C2 |
| IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2678305C1 |
| SUBSTITUTED BENZENE COMPOUNDS | 2013 |
|
RU2658919C2 |
| TETRAHYDROIMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2697090C1 |
| HETEROCYCLIC COMPOUNDS, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2015 |
|
RU2667498C2 |
| DERIVATIVES OF INDOLIN-2-SHE AS INHIBITORS OF PROTEINKINAS | 2013 |
|
RU2627706C2 |
